On December 18, 2025, Skye Bioscience, Inc. entered into a non-exclusive collaboration and license agreement with Halozyme, allowing Skye to use Halozyme's drug delivery technology for a new formulation of nimacimab, with milestone and royalty payments based on sales. This is a significant event as it opens new development opportunities for the company.